Augustine secures $85m to advance Charcot-Marie-Tooth candidate
Augustine Therapeutics has raised €78m ($85m) in funding to support the development of its lead candidate as it enters a Phase I/II trial in Charcot-Marie-Tooth (CMT) disease.
Augustine Therapeutics has raised €78m ($85m) in funding to support the development of its lead candidate as it enters a Phase I/II trial in Charcot-Marie-Tooth (CMT) disease.
What's Your Reaction?
